The active molecule in Fiasp® is identical to NovoLog®.
The Fiasp® formulation contains the addition of Vitamin B3 (niacinamide) and an amino acid (L-Arginine), to stabilize the formulation.2
The active molecule in Fiasp® is identical to NovoLog®.
The Fiasp® formulation contains the addition of Vitamin B3 (niacinamide) and an amino acid (L-Arginine), to stabilize the formulation.2
Fiasp® can be dosed at mealtime or within 20 minutes after starting a meal.1
Instruct patients on basal-bolus treatment who forget a mealtime dose to monitor their blood glucose level to decide if an insulin dose is needed, and to resume their usual dosing schedule at the next meal.
There is a 1:1 dosing conversion for patients already on mealtime insulin.1
Patients may forget to take their dose before starting to eat, but instead of skipping the dose they can take Fiasp® within 20 minutes of starting.
Changes in insulin, insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Dose adjustments may be needed to reduce the risk of hypoglycemia or hyperglycemia.1
Fiasp® (insulin aspart injection) 100 U/mL is a rapid-acting insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Please click here for Prescribing Information.
NovoLog® (insulin aspart injection) 100 U/mL is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.
NovoLog® continuous subcutaneous infusion route (insulin pump): Do not mix NovoLog® with any other insulin or diluent.
Please click here for Prescribing Information.
References: